MediWound sees FY25 revenue $17M, consensus $22.98M

MediWound (MDWD) provided a corporate and financial update ahead of its participation in the J.P. Morgan Healthcare Conference. “As we enter 2026, we are encouraged by the momentum we’ve built as we continue to execute on our growth strategy, with meaningful progress across both our clinical pipeline and operational platform,” said Ofer Gonen, CEO. “Over the past year, we advanced our Phase III VALUE trial toward key milestones, positioned the EscharEx program for expansion into additional chronic wound indications, strengthened our balance sheet, and completed the expansion of our NexoBrid manufacturing facility, which is now fully operational. While U.S. government shutdown-related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these effects are timing-related, and that we now have the key elements in place to continue executing our strategy, as reflected in our revised three-year revenue guidance.”